scholarly journals Micronutrients and Benefits of Supplementation for Reducing the Risk of Progression of Age-related Macular Degeneration – An Update

2018 ◽  
Vol 12 (1) ◽  
pp. 39 ◽  
Author(s):  
Maurizio Battaglia Parodi ◽  
Maria Rosaria Mollo ◽  
Andrea Brunoro ◽  
Alessandro Arrigo ◽  
Francesco Romano ◽  
...  

Retina ◽  
2019 ◽  
Vol 39 (5) ◽  
pp. 918-925 ◽  
Author(s):  
Anton M. Kolomeyer ◽  
Maureen G. Maguire ◽  
Wei Pan ◽  
Brian L. VanderBeek

2018 ◽  
Vol 10 (466) ◽  
pp. eaat4544 ◽  
Author(s):  
Anna C. S. Tan ◽  
Matthew G. Pilgrim ◽  
Sarah Fearn ◽  
Sergio Bertazzo ◽  
Elena Tsolaki ◽  
...  

Drusen are lipid-, mineral-, and protein-containing extracellular deposits that accumulate between the basal lamina of the retinal pigment epithelium (RPE) and Bruch’s membrane (BrM) of the human eye. They are a defining feature of age-related macular degeneration (AMD), a common sight-threatening disease of older adults. The appearance of heterogeneous internal reflectivity within drusen (HIRD) on optical coherence tomography (OCT) images has been suggested to indicate an increased risk of progression to advanced AMD. Here, in a cohort of patients with AMD and drusen, we show that HIRD indicated an increased risk of developing advanced AMD within 1 year. Using multimodal imaging in an independent cohort, we demonstrate that progression to AMD was associated with increasing degeneration of the RPE overlying HIRD. Morphological analysis of clinically imaged cadaveric human eye samples revealed that HIRD was formed by multilobular nodules. Nanoanalytical methods showed that nodules were composed of hydroxyapatite and that they differed from spherules and BrM plaques, other refractile features also found in the retinas of patients with AMD. These findings suggest that hydroxyapatite nodules may be indicators of progression to advanced AMD and that using multimodal clinical imaging to determine the composition of macular calcifications may help to direct therapeutic strategies and outcome measures in AMD.


2020 ◽  
Vol 9 (2) ◽  
pp. 25 ◽  
Author(s):  
Alauddin Bhuiyan ◽  
Tien Yin Wong ◽  
Daniel Shu Wei Ting ◽  
Arun Govindaiah ◽  
Eric H. Souied ◽  
...  

2020 ◽  
Vol 9 (10) ◽  
pp. 12
Author(s):  
Anne M. Lynch ◽  
Brandie D. Wagner ◽  
Alan G. Palestine ◽  
Nebojsa Janjic ◽  
Jennifer L. Patnaik ◽  
...  

2018 ◽  
Vol 115 (4) ◽  
pp. E696-E704 ◽  
Author(s):  
Demetrios G. Vavvas ◽  
Kent W. Small ◽  
Carl C. Awh ◽  
Brent W. Zanke ◽  
Robert J. Tibshirani ◽  
...  

We evaluated the influence of an antioxidant and zinc nutritional supplement [the Age-Related Eye Disease Study (AREDS) formulation] on delaying or preventing progression to neovascular AMD (NV) in persons with age-related macular degeneration (AMD). AREDS subjects (n = 802) with category 3 or 4 AMD at baseline who had been treated with placebo or the AREDS formulation were evaluated for differences in the risk of progression to NV as a function of complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) genotype groups. We used published genetic grouping: a two-SNP haplotype risk-calling algorithm to assess CFH, and either the single SNP rs10490924 or 372_815del443ins54 to mark ARMS2 risk. Progression risk was determined using the Cox proportional hazard model. Genetics–treatment interaction on NV risk was assessed using a multiiterative bootstrap validation analysis. We identified strong interaction of genetics with AREDS formulation treatment on the development of NV. Individuals with high CFH and no ARMS2 risk alleles and taking the AREDS formulation had increased progression to NV compared with placebo. Those with low CFH risk and high ARMS2 risk had decreased progression risk. Analysis of CFH and ARMS2 genotype groups from a validation dataset reinforces this conclusion. Bootstrapping analysis confirms the presence of a genetics–treatment interaction and suggests that individual treatment response to the AREDS formulation is largely determined by genetics. The AREDS formulation modifies the risk of progression to NV based on individual genetics. Its use should be based on patient-specific genotype.


2001 ◽  
Vol 58 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Ursula Körner-Stiefbold

Die altersbedingte Makuladegeneration (AMD) ist eine der häufigsten Ursachen für einen irreversiblen Visusverlust bei Patienten über 65 Jahre. Nahezu 30% der über 75-Jährigen sind von einer AMD betroffen. Trotz neuer Erkenntnisse in der Grundlagenforschung ist die Ätiologie, zu der auch genetische Faktoren gehören, noch nicht völlig geklärt. Aus diesem Grund sind die Behandlungsmöglichkeiten zum jetzigen Zeitpunkt noch limitiert, so dass man lediglich von Therapieansätzen sprechen kann. Die derzeit zur Verfügung stehenden Möglichkeiten wie medikamentöse, chirurgische und laser- und strahlentherapeutische Maßnahmen werden beschrieben.


2018 ◽  
Author(s):  
Rebekah Stevens ◽  
Richard Cooke ◽  
Hannah Bartlett

Sign in / Sign up

Export Citation Format

Share Document